Scott Ensign has a word stenciled on the wall behind his desk, put there to remind him of the one thing he says he is bad at. It is not a word ad tech executives usually admit they need. We will get to it.
Scott Ensign is chief strategy officer at Butler/Till, an independent, employee-owned media agency with deep roots in health and pharma. Which is why the most important thing he said in this interview should make every pharma brand manager sit up.
We were recording in April 2025, with talk swirling of a ban on pharma ads on TV. I asked him to defend his strangest opinion, one I share: that fewer ad impressions would be good. He went further than good. “I think it's more than good. I think it's necessary and great.”
Then he connected it to the ban, and did not spare his own category.
“If you watch linear TV, you will see pharma ad after pharma ad after pharma ad. If you think about advertising waste, just like any other kind of waste, there are byproducts of waste. And I think one of the byproducts of advertising waste is consumer distrust, acrimony towards advertising, and really that's manifesting itself right now in some policy.”
And then he named the viewer. “Somebody like RFK Jr. is probably watching a lot of linear TV. He's in the age cohort of people who watch a lot of linear TV, at 71, 72 years old. And he's probably seeing all of these irrelevant pharma ads, untargeted, and that's driving policy decisions.”
Read that slowly. An agency that buys pharma media is saying the industry's untargeted flood helped hand the government its argument. Not the regulators. Not the activists. The carpet bombing. The theory that the health secretary formed his views on drug advertising from the commercial breaks during his own evening TV is speculation, and Ensign framed it as such. But the mechanism is not. Show the same audience the same irrelevant ad often enough and you are no longer advertising to them. You are radicalizing them.
His prescription is the opposite of the reach-and-frequency playbook. “Ads are going to continue to get more targeted, they're going to continue to be more permission-based, therefore they will be more valuable, and yes, on a per-unit basis they will ultimately be more expensive. But the result is consumers will be exposed to fewer messages that are far more relevant and valuable to them.”
The value exchange, in his words, has to be treated responsibly. “We cannot bombard them with irrelevant things. And we can't chase the cheap solutions.”
19 percent
The cheap solutions are where his other number comes from. A couple of years back, during the made-for-advertising panic, Butler/Till started measuring more closely on a large client's buy. What they found, he says: “In some cases, 19 percent of what I would consider MFA inventory. Again, it's not fraud, but it's just not exactly what you would want your brands associated with.”
Nearly a fifth. On a big client. Inside a programmatic plan someone was presumably proud of. They partnered with Chris Kane's company, Jounce, combined its data with their own performance metrics, and built filters they now run on every campaign. About 70 percent of their programmatic spend now goes through deals; the open-exchange remainder runs behind tight guardrails.
I mentioned Kane had been on the show the week before and said he regretted making publishers into villains. Ensign agreed, with an analogy he admitted was a little extreme. “I've compared that whole situation to the war on drugs a little bit. If you don't address what's going on in the demand side, supply is going to be there as long as there's demand.” I added the obvious punchline: the biggest problem in the drug war is the buyers. “Exactly.”

